Discover how CRISPR screening technology is identifying novel epigenetic co-factors of oncogenic AR-activity in prostate cancer treatment resistance.
Examining disparities in next-generation sequencing testing access between Medicare Advantage and Traditional Medicare for metastatic prostate cancer patients.